Purity Test of Epirubicin Hydrochloride with Reference to the Japanese Pharmacopoeia

Importance of the topic

The accurate determination of residual solvents in epirubicin hydrochloride is critical to ensure patient safety, maintain drug efficacy and comply with pharmacopeial standards. Residual solvents such as acetone, methanol, ethanol and 1-propanol must be monitored to prevent toxicological risks and guarantee the quality of chemotherapy agents.

Aims and Study Overview

This study describes a gas chromatography method with flame ionization detection (GC-FID) aligned with the Japanese Pharmacopoeia to quantify trace levels of common solvents in epirubicin hydrochloride. The main objectives were to establish resolution, repeatability and suitability of the procedure for routine quality control.

Methodology

Standard solutions of target solvents were prepared in N,N-dimethylformamide at specified concentrations. Separation was achieved on a polyethylene glycol column using a temperature program from 40 °C to 130 °C. Key performance metrics included chromatographic resolution between acetone and the internal standard (1,4-dioxane) and the relative standard deviation (RSD) for peak areas.

Instrumentation Used

• Gas chromatograph with flame ionization detector (GC-FID)
• InertCap WAX capillary column, 0.53 mm I.D. × 30 m, film thickness 1.00 µm
• Helium carrier gas at 25 kPa
• Split injection mode (1:15) at 120 °C, injection volume 1.0 µL
• Detector temperature 150 °C, FID range 10^0

Main Results and Discussion

The method achieved a resolution of 32.1 between acetone and the internal standard, indicating excellent peak separation. Repeatability tests (n=6) showed RSD values of 0.5% for acetone, 2.1% for methanol, 0.4% for ethanol, 0.4% for 1-propanol and 0.5% for the internal standard. These results demonstrate high precision and suitability for trace solvent analysis.

Benefits and Practical Applications

This GC-FID procedure offers a robust, reproducible and pharmacopeia-compliant approach for residual solvent testing in pharmaceutical manufacturing. It supports quality assurance departments in release testing, stability studies and regulatory submissions, ensuring patient safety and product integrity.

Future Trends and Potential Applications

Advancements may include faster analysis through high-throughput columns, integration with mass spectrometry for enhanced specificity, adoption of green solvents and automation of sample preparation. Emerging techniques like micro-GC and hyphenated detectors could further improve sensitivity and reduce analysis times.

Conclusion

The described GC-FID method meets Japanese Pharmacopoeia requirements for solvent purity testing in epirubicin hydrochloride. With excellent resolution and precision, it provides a reliable tool for pharmaceutical quality control.